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http://dx.doi.org/1shown to increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density
lipoprotein cholesterol (LDL-C) levels, as monotherapy or in combination with statins. In
this study, 165 Japanese patients with elevated LDL-C or low HDL-C levels were randomly
assigned to receive placebo, evacetrapib monotherapy 30 mg, 100 mg, or 500 mg, ator-
vastatin 10 mg, or evacetrapib 100 mg in combination with atorvastatin 10 mg. After 12
weeks, evacetrapib monotherapy increased HDL-C levels by 74%, 115%, and 136% and
decreased LDL-C levels by 15%, 23%, and 22% and CETP activity by 50%, 83%, and 95%
(for the 30-mg, 100-mg, and 500-mg dose groups, respectively) versus placebo. In combi-
nation with atorvastatin 10 mg, evacetrapib 100 mg increased HDL-C levels by 103% and
decreased LDL-C levels by 15% and CETP activity by 68% versus atorvastatin alone. After
a 4- to 6-week washout, HDL-C, LDL-C, and CETP mass and activity returned to baseline
levels in the evacetrapib-treated groups, and most patients had evacetrapib concentrations
below the quantitation limit. Evacetrapib monotherapy or in combination with atorvastatin
was not likely to be associated with any signiﬁcant change in blood pressure and did not
have any adverse effects on mineralocorticoid or glucocorticoid measures. Notably, plasma
evacetrapib concentrations were mostly undetectable, and all pharmacodynamic bio-
markers (HDL-C and LDL-C levels and CETP mass and activity) returned to baseline after
a 4- to 6-week washout. In conclusion, evacetrapib as monotherapy or in combination with
atorvastatin effectively decreased CETP activity and LDL-C levels and increased HDL-C
levels after 12 weeks in Japanese patients with dyslipidemia.  2014 The Authors.
Published by Elsevier Inc. All rights reserved. (Am J Cardiol 2014;113:2021e2029)Although pharmacologic inhibition of cholesteryl ester
transfer protein (CETP) leads to substantial increase in high-
density lipoprotein cholesterol (HDL-C) and signiﬁcant
decrease in low-density lipoprotein cholesterol (LDL-C)
levels, torcetrapib resulted in an increased risk of cardio-
vascular (CV) morbidity and mortality, and dalcetrapib was
not different from placebo in reducing CV events. Treatment
with torcetrapib, but not with other CETP inhibitors, was also
associated with signiﬁcant increase in blood pressure (BP)
and plasma sodium, bicarbonate, and aldosterone levels and
decrease in potassium levels.1 Moreover, recent data show
that persistent effects on lipids and residual plasma levels of
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0.1016/j.amjcard.2014.03.045and Tolerability of CETP Inhibition With Anacetrapib
(DEFINE) trial,2 and similar ﬁndings were also reported
during a Japanese phase 2b study (8-week treatment with
anacetrapib followed by an 8-week off-drug reversal
period).3 Evacetrapib has been shown to inhibit CETP ac-
tivity both in human plasma and in a human CETP transgenic
mouse model, without increases in aldosterone or BP.4 In a
phase 1 study conducted in healthy Japanese subjects,
evacetrapib was well tolerated when administered for 14 days
over the dose range of 30 to 600 mg and signiﬁcantly
increased HDL-C and decreased LDL-C levels.5 In a 12-
week phase 2 study conducted in the United States and
Europe, evacetrapib raised HDL-C levels up to 129% and
lowered LDL-C up to 36% in nearly 400 patients with dys-
lipidemia and was also well tolerated without showing any
adverse effect on either BP or mineralocorticoid levels.6 The
present study evaluated efﬁcacy, safety, tolerability, and
pharmacokinetic proﬁle of evacetrapib monotherapy at doses
up to 500 mg and evacetrapib 100 mg in combination with
10 mg of atorvastatin in Japanese patients with dyslipidemia.
Methods
This study was a multicenter, randomized, double-blind,
parallel group, placebo- and active-controlled, phase 2,
dose-response study (ClinicalTrials.gov identiﬁer is
NCT01375075). The institutional review boards of allwww.ajconline.org
Figure 1. Patient disposition. AE ¼ adverse events; DC ¼ discontinued; NM ¼ not met; PD ¼ patient decision.
Table 1
Baseline characteristics
Variable Placebo
(n ¼ 28)
EVA 30 mg
(n ¼ 27)
EVA 100 mg
(n ¼ 28)
EVA 500 mg
(n ¼ 27)
ATO 10 mg
(n ¼ 27)
ATO 10 mg plus
EVA 100 mg (n ¼ 28)
Age (years), mean  SD 50  9.6 49  11 48  12 49  8.1 49  8.8 50  10
Female 10 (36%) 8 (30%) 10 (36%) 9 (33%) 8 (30%) 10 (36%)
Height (cm), mean  SD 166  8.6 165  9.5 165  10 167  9.3 167  6.8 165  8.3
Weight (kg), mean  SD 69  14 69  14 66  12 69  16 67  13 70  18
Body mass index (kg/m2),
mean  SD
25  3.7 25  3.4 24  3.2 24  4.1 24  3.3 26  5.5
LDL-C (mg/dL), mean  SD 140  27 144  24 144  23 143  30 134  32 140  20
HDL-C (mg/dL), mean  SD 51  14 50  13 52  16 49  11 49  14 52  14
Triglycerides (mg/dL), median
(range)
119 (47, 303) 142 (50, 380) 124 (52, 355) 134 (55, 379) 147 (49, 322) 118 (50, 296)
ATO ¼ atorvastatin; EVA ¼ evacetrapib; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; n ¼ number of
patients; SD ¼ standard deviation.
2022 The American Journal of Cardiology (www.ajconline.org)participating centers approved the protocol, and all patients
provided written informed consent. This 12-week study
includedplacebo, evacetrapibmonotherapy (30mg, 100mg, or
500 mg), atorvastatin 10 mg monotherapy, or evacetrapib
100 mg in combination with atorvastatin 10 mg, administered
orally once daily.
The study included 4 consecutive phases: screening, diet
lead-in/washout, treatment, and follow-up. After screening,
eligible patients were instructed to discontinue lipid-related
medications and begin a diet therapy in accordance with the
Japan Atherosclerosis Society guidelines for diagnosis and
prevention of atherosclerotic CV disease.7 The diet lead-in/washout phase was either 2 weeks (for patients not taking any
lipid-modifyingmedication) or 4weeks (for those undergoing
washout of statins, ezetimibe, bile acid sequestrants, ethyl
icosapentate, or over-the-counter medications or health foods
used to treat lipids).
Patients who remained eligible after following the diet
lead-in/washout phase were equally randomized into 1 of the
6 treatment groups: placebo, evacetrapib monotherapy
(30mg, 100mg, or 500mg), atorvastatin 10mgmonotherapy,
or evacetrapib 100 mg in combination with atorvastatin
10mg. Randomization was performed by an interactive voice
response system and was stratiﬁed by baseline levels of
Table 2
Change from baseline to week 12 in serum lipid measurements
Measures Placebo
(n ¼ 28)
EVA 30 mg
(n ¼ 27)
EVA 100 mg
(n ¼ 27)
EVA 500 mg
(n ¼ 27)
ATO 10 mg
(n ¼ 27)
ATO 10 mg plus
EVA 100 mg (n ¼ 28)
LDL-C (mg/dL)
Baseline 140  27 144  24 145  22 143  30 134  32 140  20
Week 12 141  30 122  28 111  24 108  36 84  28 61  17
Percentage change 1.2  3.4 14  3.5 22  3.4 21  3.6 38  3.4 52  3.5
Relative change 15 (24, 7.4)* 23 (31, 15)** 22 (30, 14)** 15 (23, 6.6)***
HDL-C (mg/dL)
Baseline 51  14 50  13 53  16 49  11 49  14 52  14
Week 12 54  16 91  27 111  30 125  34 57  14 109  30
Percentage change 8.0  8.8 82  8.9 123  8.9 144  9.2 17  8.9 121  8.9
Relative change 74 (53, 95)** 115 (95, 136)** 136 (115, 157)** 103 (82, 124)**
Triglycerides (mg/dL)
Baseline 119 (47, 303) 142 (50, 380) 124 (52, 355) 134 (55, 379) 147 (49, 322) 118 (50, 296)
Week 12 115 (54, 324) 123 (59, 392) 100 (58, 390) 115 (46, 797) 88 (50, 231) 95 (38, 199)
Percentage change 5.1  9.7 3.7  9.9 12  9.7 12  10 25  9.7 21  10
Relative change 1.3 (24, 22) 6.8 (16, 30) 7.0 (16, 30) 3.5 (20, 27)
Baseline and week 12 values for LDL-C and HDL-C are mean  SD. Baseline and week 12 values for triglycerides are median (range). Percentage changes
are LS mean  SE in percentage changes from baseline. Relative changes are differences of LS mean with 90% CI in percentage changes from baseline
between evacetrapib monotherapy groups vs. placebo or between atorvastatin þ evacetrapib combination therapy group vs. atorvastatin monotherapy, based on
MMRM analysis.
ATO ¼ atorvastatin; CI ¼ conﬁdence interval; EVA ¼ evacetrapib; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
cholesterol; LS ¼ least square; MMRM ¼ mixed-effect model repeated measure; n ¼ number of patients; SD ¼ standard deviation; SE ¼ standard error.
*p-value ¼ .002; **p-value <.001; ***p-value ¼ .003.
Table 3
Change from baseline to week 12 in corrected cholesteryl ester transfer protein activity and cholesteryl ester transfer protein mass
Measures Placebo
(n ¼ 28)
EVA 30 mg
(n ¼ 27)
EVA 100 mg
(n ¼ 27)
EVA 500 mg
(n ¼ 27)
ATO 10 mg
(n ¼ 27)
ATO 10 mg plus
EVA 100 mg
(n ¼ 28)
CETP activity (pmol/mL/min)
Baseline 22  4.6 21  4.3 23  4.8 23  6.4 23  6.2 23  6.9
Week 12 24  6.1 12  4.1 5.7  3.3 3.1  3.2 21  6.7 5.7  4.7
Percentage change 9.2  3.5 41  3.6 74  3.6 85  3.7 5.7  3.5 73  3.7
Relative change 50 (59, 42)* 83 (91, 75)* 95 (103, 86)* 68 (76, 59)*
CETP mass (mg/mL)
Baseline 2.3  0.5 2.2  0.5 2.3  0.4 2.3  0.5 2.2  0.4 2.4  0.5
Week 12 2.4  0.5 4.2  1.1 5.3  1.7 5.7  1.7 2.0  0.4 4.6  1.5
Percentage change 5.8  11 87  31 127  55 152  71 8.6  12 93  41
Relative change 1.8 (1.3, 2.3)* 2.8 (2.3, 3.3)* 3.2 (2.7, 3.7)* 2.1 (1.7, 2.6)*
CETP activity results are corrected for the maximum inhibitable CETP activity with evacetrapib by visit. Baseline and week 12 values for CETP activity and
CETP mass are mean  SD. Percentage change for CETP activity is LS mean  SE in percentage change from baseline. Percentage change for CETP mass is
mean  SD. Relative changes are differences of LS mean with 90% CI in percentage changes (CETP activity) or absolute changes (CETP mass) from baseline
between evacetrapib monotherapy groups vs. placebo or between atorvastatin þ evacetrapib combination therapy group vs. atorvastatin monotherapy, based on
MMRM analysis.
ATO ¼ atorvastatin; CETP ¼ cholesteryl ester transfer protein; CI ¼ conﬁdence interval; EVA ¼ evacetrapib; LS ¼ least square; MMRM ¼ mixed-effect
model repeated measure; n ¼ number of patients; SD ¼ standard deviation; SE ¼ standard error.
*p-value <.001.
Preventive Cardiology/Evacetrapib in Japanese Patients With Dyslipidemia 2023serum triglycerides (<150 or 150 mg/dl) and HDL-C
(<45 or 45 mg/dl for men; <50 or 50 mg/dl for
women). A follow-up visit was conducted 4 weeks (þ2-week
allowance) after cessation of the study drug.
Men and women aged 20 years were included in this
study. Eligible patients were required to meet either low
HDL-C or high LDL-C lipid criteria. Patients meeting the
low HDL-C criteria had an HDL-C level of <45 mg/dl for
men or <50 mg/dl for women, plus LDL-C <190 mg/dl
(and 0 to 1 risk factors), <160 mg/dl (and 2 risk factors), or<130 mg/dl (and 3 risk factors). Patients meeting the high
LDL-C criteria had an LDL-C level of >100 mg/dl but
<190 mg/dl (and 0 to 1 risk factors), <160 mg/dl (and 2 risk
factors), or <130 mg/dl (and 3 risk factors). Risk factors
were deﬁned as age (men 45 years, women 55 years),
hypertension, diabetes (including impaired glucose toler-
ance), smoking, family history of coronary artery disease
(assessed by the clinical investigator), and low HDL-C
(<40 mg/dl).7 All patients were required to have a fasting
triglyceride level of <400 mg/dl.
Figure 2. Change over time from baseline through follow-up in (A)HDL-C and (B) LDL-C results. The follow-up visit was conducted 4 to 6 weeks after cessation
of the study drug. ATO ¼ atorvastatin; DIRECT ¼ LDL-C determined using the direct method; EVA ¼ evacetrapib; FU ¼ follow-up; SE ¼ standard error.
Figure 3. Change over time from baseline through follow-up in (A) CETP activity and (B) CETP mass results. The follow-up visit was conducted 4 to 6 weeks
after cessation of the study drug. ATO ¼ atorvastatin; EVA ¼ evacetrapib; FU ¼ follow-up; SE ¼ standard error.
2024 The American Journal of Cardiology (www.ajconline.org)Patients were excluded if they had any clinical manifesta-
tions of coronary heart disease (stable or unstable angina pec-
toris, acute coronary syndrome, or myocardial infarction) or a
coronary revascularization procedure including stent place-
ment, symptomatic carotid artery disease, or symptomatic pe-
ripheral arterial disease. Patients were also excluded if they had
a systolic blood pressure (SBP) of >140 mm Hg or diastolic
blood pressure (DBP) >90 mm Hg, had symptoms consistent
with moderate or severe heart failure, or had an electrocardio-
graphic abnormality consistent with QTc prolongation, wide
QRS complexes, atrial ﬁbrillation, congenital long QT syn-
drome, or history of ventricular tachycardia. Other exclusion
criteria were recent history of a rash, chronic skin disorder
(psoriasis, eczema, or urticaria), or history of any drug-related
rash; patients expected to start, or were unwilling to undergo
adequate washout of, lipid-modifying therapies (as described
previously); and patients taking probucol, ﬁbrate, or nicotinic
agents within 8 weeks before screening.
Patients were examined during scheduled visits at weeks
2, 4, 8, and 12 (during the treatment phase), and at the
follow-up visit, and were required to fast for at least 8 hours
before sample collections. Serum lipid parameters
(including total cholesterol, LDL-C, HDL-C, and triglycer-
ide levels) were measured at all visits, and CETP activity
and mass were measured at weeks 4, 8, and 12 and at the
follow-up visit. Plasma evacetrapib concentrations were also
measured before and after dose at weeks 2, 4, 8, and 12 and
at the follow-up visit.Screening laboratory tests were performed locally; all
other laboratory tests were performed at a central laboratory
(Covance Central Laboratory Services, Indianapolis, Indi-
ana). Plasma concentrations of evacetrapib were measured
at Bioanalytical Systems, Inc. (West Lafayette, Indiana) and
were assayed using a validated liquid chromatography-
tandem mass spectrometry method. Measurement of CETP
mass in serum samples was performed by enzyme-linked
immunosorbent assay. Serum CETP activity was measured
by ﬂuorometric assay and expressed after correction for the
maximum inhibitable CETP activity with evacetrapib.
Safety was evaluated by means of adverse event assess-
ment, clinical laboratory tests, vital signs (BP and pulse in
sitting position), electrocardiograms, and rash assessment.
Rash evaluation included history and examination, rash
photography, laboratory assessments, and rash punch biopsy
for nonlocalized, clinically signiﬁcant rashes. Skin biopsies
were read by a central dermatopathologist. Rash cases were
adjudicated by a central dermatologist blinded to study
treatment.
Assuming SDs of 30% and 25% for percent changes in
HDL-C and LDL-C, respectively, Pearson correlation co-
efﬁcient of 0.4 between changes, and a 15% dropout rate of
enrolled patients, a sample size of 25 patients randomized to
each treatment group (22 completers per treatment group)
was calculated to provide 83% power to simultaneously
detect a 40% increase from baseline in HDL-C and a 20%
decrease from baseline in LDL-C in patients treated with
Figure 4. Drug exposure on treatment and after a 4-week washout. The horizontal lines show the median of concentrations by week and treatment group. The
evacetrapib 100-mg group includes patients receiving monotherapy and patients receiving combination therapy with atorvastatin. *N and n displayed at the top
of the plot indicate the numbers of all pharmacokinetic observations (N, including observations below the LOQ) and patients (n) who had pharmacokinetic
observations. **N and n displayed at the bottom of the plot indicate the number of observations (N) below the LOQ and the number of patients (n) who had
observations below the LOQ. ***A concentration value of approximately 91 ng/ml at week 16 to 18 at 30 mg was excluded as an outlier as the log-transformed
value was greater than the arithmetic mean þ 3 times the SD of the remaining log-transformed values at week 16 to 18. LOQ ¼ limit of quantitation (1 ng/ml);
N ¼ number of observations; n ¼ number of patients.
Table 4
Safety data
Variable Placebo
(n ¼ 28)
EVA 30 mg
(n ¼ 27)
EVA 100 mg
(n ¼ 28)
EVA 500 mg
(n ¼ 27)
ATO 10 mg
(n ¼ 27)
ATO 10 mg plus
EVA 100 mg
(n ¼ 28)
TEAEs 9 (32%) 12 (44%) 12 (43%) 11 (41%) 10 (37%) 11 (39%)
Study drug-related TEAEs 1 (3.6%) 4 (15%) 2 (7.1%) 3 (11%) 3 (11%) 3 (11%)
Adverse events leading to discontinuation 1 (3.6%) 0 0 3 (11%) 0 1 (3.6%)
Serious adverse events 1 (3.6%) 0 0 1 (3.6%) 0 0
ALT > 3x ULN 0 0 0 1 (3.7%) 1 (3.7%) 1 (3.6%)
AST > 3x ULN 0 0 0 0 1 (3.7%) 1 (3.6%)
Creatine kinase >5x ULN 1 (3.6%) 1 (3.7%) 1 (3.6%) 0 1 (3.7%) 0
Elevation in SBP 15 mm Hg 4 (14%) 6 (22%) 5 (18%) 7 (26%) 6 (22%) 5 (18%)
Elevation in DBP 10 mm Hg 10 (36%) 13 (48%) 7 (25%) 12 (44%) 7 (26%) 9 (32%)
Treatment-emergent adverse events (TEAEs) are deﬁned as an adverse event beginning after the ﬁrst dose of study drug or an adverse event that increases in
severity after the ﬁrst dose of study drug.
ALT¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; ATO¼ atorvastatin; DBP¼ diastolic blood pressure; EVA¼ evacetrapib; n ¼ number
of patients; SBP ¼ systolic blood pressure; TEAE ¼ treatment-emergent adverse event; ULN ¼ upper limit of normal.
Preventive Cardiology/Evacetrapib in Japanese Patients With Dyslipidemia 2025evacetrapib compared with placebo (2-sided t test, signiﬁ-
cance level 0.1).
The intent-to-treat (ITT) population was deﬁned as ran-
domized patients who received at least 1 dose of study treat-
ment. The modiﬁed ITT population consisted of ITT patients
who had at least 1 baseline measurement and 1 postbaseline
HDL-C measurement. Efﬁcacy analyses were conducted for
the active treatment phase on the modiﬁed ITT population.
Safety analyses were conducted on the ITT population.
The primary efﬁcacy analysis of the primary variables
was restricted maximum likelihoodebased mixed-effects
model for repeated measures with baseline measurement
as covariate; treatment, visit (weeks 2, 4, 8, or 12), andtreatment-by-visit interaction as ﬁxed effects; and patient as
a random effect. Least squares (LS) means, LS mean dif-
ferences, 90% conﬁdence intervals, and p values were
reported by treatment and by visit.
CETP activity and percent change from baseline, as well as
CETP mass and change from baseline, were analyzed using a
similar mixed-effects model for repeated measures with
treatment, visit (weeks 4, 8, or 12), and treatment-by-visit
interaction as ﬁxed effects; baseline measurement as a co-
variate; and patient as a random effect with LS means, LS
mean differences, 90% conﬁdence intervals, and p values
being reported by treatment and by visit. A mixed-effects
model for repeated measures with baseline measurement,
Figure 5. Box-and-whisker plot of BP from baseline through week 12: (A) SBP (mm Hg) and (B) DBP (mm Hg). The symbol in the box interior represents the
mean. The horizontal line in the box interior represents the median. The length of the box represents the interquartile range. The whiskers are drawn to the most
extreme points that lie within the fences. The upper fence is deﬁned as the third quartile plus 1.5 times the interquartile range. The lower fence is deﬁned as the
ﬁrst quartile minus 1.5 times the interquartile range. ATO ¼ atorvastatin; EVA ¼ evacetrapib.
2026 The American Journal of Cardiology (www.ajconline.org)treatment, visit, and treatment by visit as independent vari-
ables was used to analyze vital signs and laboratory param-
eters (i.e., mineralocorticoid and electrolytes).
No formal adjustment for multiplicity was made for all
planned efﬁcacy and safety analyses. Unless otherwise
speciﬁed, data were analyzed with a 2-sided signiﬁcance
level of 0.1. Statistical analyses were carried out using SAS
(SAS Institute, Cary, North Carolina).
Results
From June 2011 to November 2011, a total of 225 patients
were screened at 15 sites in Japan. A total of 165 patients were
randomized and a total of 156 patients completed the study by
March 2012. The disposition of these patients is shown in
Figure 1. Baseline characteristics of the patients were similar
among the different treatment groups studied and are listed in
Table 1. The mean age of patients was 49 years, and 67% of
the patients were male. The baseline lipid proﬁle was char-
acterized by mean LDL-C, HDL-C, and triglycerides of
141 mg/dl, 51 mg/dl, and 143 mg/dl, respectively. Sixty-
seven of 165 patients (41%) met the low HDL-C criteria
(<45 mg/dl for men or <50 mg/dl for women).
Evacetrapib treatment for 12 weeks in Japanese patients
with hypercholesterolemia or low HDL-C resulted in statisti-
cally signiﬁcant dose-related increases in HDL-C and
decreases in LDL-C. Percent changes in HDL-C, LDL-C, and
triglycerides are summarized in Table 2. The relative changes
in HDL-C between evacetrapib monotherapy and placebo
were 74%, 115%, and 136% for the 30-mg, 100-mg, and
500-mg treatment groups, respectively. The relative changes
in LDL-C between monotherapy and placebo were
15%,23%, and22% for the 30-mg, 100-mg, and 500-mg
dose groups, respectively. When evacetrapib 100 mg was
administered in combination with atorvastatin 10 mg, the
magnitude of change inHDL-C (þ103%) and LDL-C (15%)
levels relative to atorvastatin alone was similar to that of
evacetrapib 100 mg as monotherapy.
No statistically signiﬁcant difference was observed in
percent change in fasting triglycerides with evacetrapib
monotherapy compared with placebo or with evacetrapib incombination with atorvastatin compared with atorvastatin
alone.
Percent changes in CETP activity and CETP mass are
summarized in Table 3. The relative changes in corrected
CETP activity between evacetrapib monotherapy and placebo
were 50%, 83%, and 95% for the 30-mg, 100-mg, and
500-mg dose groups, respectively. When evacetrapib 100 mg
was administered in combination with atorvastatin 10 mg, the
decrease in CETP activity relative to atorvastatin alone
was 68%. The mean baseline CETP mass was from 2.2 to
2.4 mg/ml for all groups. At 12 weeks, CETP mass decreased
(9% on average) in the atorvastatin 10-mg group, whereas it
signiﬁcantly increased in a dose-dependent manner (between
82% and 139% on average) on evacetrapib monotherapy.
CETP mass also signiﬁcantly increased (88% on average)
when evacetrapib 100 mg was administered in combination
with atorvastatin 10 mg.
At the follow-up visit, HDL-C and LDL-C levels
(Figure 2) as well as CETP activity and mass (Figure 3)
returned to baseline in all evacetrapib monotherapy and
evacetrapib-plus-atorvastatin groups. Most of the patients
(87%) across all dose groups had evacetrapib concentrations
that were below the quantitation limit of the assay
(<1.00 ng/ml) at the follow-up visit, while the remaining
patients had a concentration near the quantitation limit (from
1.0 to 3.5 ng/ml; 12 of them in the 500-mg and 1 in the 100-
mg group; Figure 4).
Adverse event rates and important laboratory and BP
measurements are summarized inTable 4.Overall, 65 patients
(39%) experienced at least 1 treatment-emergent adverse
event (TEAE), but there was no statistically signiﬁcant dif-
ference in the incidence of these TEAEs across the treatment
groups. Sixteen patients (9.7%) experienced at least 1 TEAE
considered possibly related to study drug, and 5 patients
(3.0%) discontinued from the study because of an adverse
event. Frequently observed TEAEs were nasopharyngitis
(n ¼ 22, 13%), hepatic function abnormality (n ¼ 5, 3.0%),
back pain (n ¼ 4, 2.4%), gastroenteritis (n ¼ 3, 1.8%), and
headache (n ¼ 3, 1.8%), but there was no statistically sig-
niﬁcant difference in the incidence of these TEAEs across the
treatment groups. During the course of the study, 2 patients
Table 5
Baseline, week 12, and relative change from baseline to week 12 in blood pressure, mineralocorticoids, and electrolytes
Variable Placebo
(n ¼ 28)
EVA 30 mg
(n ¼ 27)
EVA 100 mg
(n ¼ 28)
EVA 500 mg
(n ¼ 27)
ATO 10 mg
(n ¼ 27)
ATO 10 mg plus
EVA 100 mg
(n ¼ 28)
SBP (mm Hg)
Baseline 119  12 119  12 118  13 118  13 120  9.8 117  13
Week 12 118  10 121  11 119  13 123  14 122  12 120  14
Absolute change 1.4  1.8 2.4  1.8 1.4  1.8 4.5  1.8 2.6  1.8 2.0  1.8
Relative change — 3.7 (0.4, 7.9) 2.8 (1.3, 6.9) 5.9 (1.7, 10)* — 0.5 (4.7, 3.6)
DBP (mm Hg)
Baseline 75  7.3 74  7.3 74  9.7 74  9.8 75  7.6 72  8.5
Week 12 75  6.4 75  7.2 74  9.4 77  9.9 77  8.2 73  8.2
Absolute Change 0.7  1.1 1.5  1.1 0.0  1.1 2.5  1.1 1.5  1.1 0.5  1.1
Relative change — 0.8 (1.7, 3.2) 0.7 (3.1, 1.8) 1.8 (0.7, 4.3) — 1.0 (3.5, 1.5)
Aldosterone (ng/dL)
Baseline 6.5  4. 1 7.0  8.1 3.7  2.4 3.9  3.0 3.9  2.3 4.4  3.2
Week 12 5.6  3.5 5.2  3.3 5.0  3.3 5.2  4.7 5.6  6.0 5.5  3.1
Absolute change 0.3  0.8 0.4  0.8 0.4  0.8 0.6  0.8 1.0  0.8 0.6  0.8
Relative change — 0.7 (2.6, 1.1) 0.04 (1.8, 1.9) 0.26 (1.7, 2.2) — 0.3 (2.2, 1.5)
Salivary cortisol (mg/dL)
Baseline 0.05  0.03 0.10  0.12 0.09  0.11 0.05  0.02 0.08  0.08 0.08  0.1
Week 12 0.06  0.04 0.06  0.02 0.09  0.15 0.06  0.05 0.08  0.09 0.06  0.04
Absolute change 0.01  0.02 0.02  0.02 0.01  0.02 0.01  0.02 0.00  0.02 0.00  0.02
Relative change — 0.00 (0.04, 0.03) 0.02 (0.01, 0.06) 0.00 (0.03, 0.04) — 0.01 (0.05, 0.03)
Sodium (mEq/L)
Baseline 140  1.7 140  1.8 141  2.1 141  1.9 141  1.4 141  1.6
Week 12 140  2.3 140  1.5 140  1.3 141  1.8 141  2.0 141  2.0
Absolute change 0.3  0.3 0.2  0.3 0.3  0.3 0.1  0.3 0.4  0.3 0.5  0.3
Relative change — 0.1 (0.6, 0.8) 0.01 (0.7, 0.7) 0.3 (0.5, 1.0) — 0.2 (0.5, 0.9)
Potassium (mEq/L)
Baseline 3.8  0.2 3.9  0.2 3.8  0.3 3.9  0.3 3.7  0.3 3.8  0.2
Week 12 3.8  0.2 3.9  0.2 3.9  0.3 3.9  0.3 3.8  0.2 3.9  0.3
Absolute change 0.01  0.1 0.02  0.1 0.1  0.1 0.1  0.1 0.01  0.1 0.1  0.1
Relative change — 0.01 (0.1, 0.1) 0.1 (0.02, 0.2) 0.1 (0.01, 0.2) — 0.1 (0.03, 0.2)
Bicarbonate (mEq/L)
Baseline 23  2.1 24  2.7 24  2.4 24  1.9 23  2.2 23  2.6
Week 12 24  2.1 24  2.9 25  2.3 24  2.4 24  2.7 25  2.9
Absolute change 0.5  0.4 0.6  0.43 0.6  0.4 0.6  0.5 0.6  0.4 1.2  0.4
Relative change — 0.1 (0.9, 1.1) 0.1 (0.9, 1.1) 0.1 (0.9, 1.1) — 0.6 (0.4, 1.6)
Baseline and week 12 values are mean  SD. Absolute changes are LS mean  SE in changes from baseline. Relative changes are differences of LS mean
with 90% CI in changes from baseline between evacetrapib monotherapy groups vs. placebo or between atorvastatin þ evacetrapib combination therapy group
vs. atorvastatin monotherapy, based on MMRM analysis.
ATO ¼ atorvastatin; CI ¼ conﬁdence interval; DBP ¼ diastolic blood pressure; EVA ¼ evacetrapib; LS ¼ least squares; MMRM ¼ mixed-effect model
repeated measures; n ¼ number of patients; SBP ¼ systolic blood pressure; SD ¼ standard deviation; SE ¼ standard error.
*p-value ¼ 0.021.
Preventive Cardiology/Evacetrapib in Japanese Patients With Dyslipidemia 2027experienced treatment-emergent serious adverse events
(SAEs). In 1 patient in the evacetrapib 500-mg treatment
group, the treatment-emergent SAEs (toxic skin eruption and
pyrexia) were judged to be related to the study drug.However,
this patient had undergone a tooth extraction and had
been treated with several medications, including a cephalo-
sporin, before developing the symptoms. This patient was
discontinued from the study as a result of the event. The
other patient (in the placebo treatment group) experienced
multiple unrelated SAEs caused by a car accident, including
sternal fracture, traumatic lung injury, and lumbar vertebral
fracture.
Skin and subcutaneous tissue adverse reactions were re-
ported in 5 patients during the active treatment phase: 3 pa-
tients in the evacetrapib 500-mg treatment group, 1 patient in
the evacetrapib 30-mg treatment group, and 1 patient in theevacetrapib 100 mg plus atorvastatin 10 mg combination
treatment group. Of these 5 events, 1 event was adjudicated to
be high-risk rash (the SAE described previously), 2 events
were adjudicated to be low-risk rashes, and 2 events were
adjudicated to be unrelated dermatoses.
Evacetrapib as monotherapy and in combination with
atorvastatin did not produce a clinically important adverse
effect to any of the clinical chemistry analytes or hematol-
ogy parameters. Overall, elevations of alanine aminotrans-
ferase and aspartate aminotransferase (>3 times the upper
limit of normal [ULN]) occurred in 3 and 2 patients,
respectively (Table 4). One of 3 patients with alanine
aminotransferase elevation and 1 of 2 patients with aspartate
aminotransferase elevation were in the atorvastatin 10-mg
treatment group. However, these increases were transient
and recovered during the study period, and no patient had
2028 The American Journal of Cardiology (www.ajconline.org)concomitant increase in alanine aminotransferase (>3 times
ULN) and total bilirubin (>2 times ULN). Creatine kinase
levels were elevated (>5 times ULN) in 4 patients (Table 4).
However, 2 of these events (1 occurring in the evacetrapib
30-mg treatment group and 1 in the placebo group) were
observed only at baseline, before administration of study
medication. The other 2 events (1 occurring in the evace-
trapib 100-mg treatment group and 1 occurring in the
atorvastatin 10-mg treatment group) were also transient.
Figure 5 illustrates box-and-whisker plots for SBP andDBP
from baseline through the end of treatment. There was no
clinically relevant change in either SBP or DBP during the
study period in any of the treatment groups. SBP signiﬁcantly
increased in the evacetrapib 500-mg treatment group compared
with placebo (evacetrapib 500-mg treatment group 4.5 
1.8 mm Hg, placebo group 1.4  1.8 mm Hg, LS mean
difference 5.9 2.5mmHg, p¼ 0.021;Table 5). Considerable
variability was observed in the different treatment groups in-
dependent of evacetrapib administration, as demonstrated by
an average decrease of 1.4 1.8 mm Hg in the placebo group
and increase of 2.6  1.8 mm Hg in the atorvastatin mono-
therapy group. Additionally, no dose-dependent effect of
evacetrapib on SBP was observed. DBP was not statistically
different among the 6 treatment groups. Moreover, the pro-
portion of patients experiencing signiﬁcant BP elevation (SBP
15 mm Hg or DBP 10 mm Hg) was not signiﬁcantly
different between treatment groups (Table 4). Follow-up re-
sults indicated that, for those patients whose BP increased from
normotensive or prehypertensive to hypertensive during the
course of the study, these observed BP increases were transient
in nature and returned to baseline levels at the follow-up visit.
Last, evacetrapib did not have any adverse effect on
mineralocorticoid or glucocorticoid measures, which included
serum aldosterone and salivary cortisol, and serum electrolytes
such as sodium, bicarbonate, and potassium (Table 5).
Discussion
The present study conﬁrmed the efﬁcacy of evacetrapib in
signiﬁcantly increasing HDL-C and decreasing LDL-C levels
in Japanese patients with dyslipidemia characterized by either
high LDL-C or low HDL-C levels. The signiﬁcant changes in
HDL-C and LDL-C levels were observed with evacetrapib as
monotherapy at all dose levels (30 mg, 100 mg, and 500 mg)
as well as in combination with atorvastatin. In this 12-week
study, the administration of evacetrapib 500 mg as mono-
therapy increased HDL-C by as much as 136% and decreased
LDL-C by as much as 22% relative to placebo. Signiﬁcant
changes persisted when evacetrapib 100 mg was given in
combination with atorvastatin 10 mg, suggesting an additive
and pharmacologically independent effect of evacetrapib on
both HDL-C and LDL-C response.
These results are comparable to those of the phase 2 study
of evacetrapib in patients with dyslipidemia from the United
States and Europe.6 Baseline LDL-C levels were similar in the
Japanese and United States/Europe studies (141 mg/dl vs
144mg/dl, respectively), whereas baseline HDL-C levels were
lower in the present study of Japanese patients with dyslipi-
demia (51 mg/dl vs 55mg/dl). The lower mean baseline HDL-
C levels could actually explain the relatively higher magnitude
of HDL-C increase observed with evacetrapib in the presentstudy, because treatment response was found to correlate with
baseline HDL-C in this study and in the global study.6
Although neither torcetrapib nor dalcetrapib demonstrated
reductions in the risk of CV events in the Investigation of Lipid
LevelManagement toUnderstand its Impact inAtherosclerotic
Events to (ILLUMINATE) trial and dalcetrapib-OUTCOMES
studies, respectively, CV risk reduction might be shown by
more potentCETP inhibitors.HDL-C increaseswere only 31%
by dalcetrapib and 61% by torcetrapib in the phase 2 studies, in
comparison with >130% by evacetrapib and anacetrapib.8
Further support in favor of positive effects of pharmacologic
CETP inhibition on atherosclerosis comes from the post hoc
analysis of the Investigation ofLipidLevelManagementUsing
Coronary Ultrasound to Assess Reduction of Atherosclerosis
by CETP Inhibition and HDL Elevation (ILLUSTRATE)
intravascular ultrasound study with torcetrapib.9 Although
treatmentwith torcetrapib did not result in any signiﬁcant effect
on percent atheroma volume,10 an inverse relation was
observed between changes in levels of HDL-C and percent
atheroma volume. Atherosclerosis regression was observed in
the highest quartile ofHDL-C levels achievedwith torcetrapib,
thus indirectly suggesting that these HDL particles are func-
tional. Indeed, experiments using HDL samples isolated from
patients after treatment with a CETP inhibitor, such as anace-
trapib and torcetrapib, indicate that HDL particles retain both
their ability to promote cholesterol transport and their anti-
inﬂammatory effects.11e13 In addition, treatment with
anacetrapib and torcetrapib were shown to promote
macrophage-to-feces reverse cholesterol transport and to in-
crease fecal excretion of bile acid and/or cholesterol in the ro-
dent models of dyslipidemia.14,15 In these experiments in
human and rodent models, an increase of reverse cholesterol
transport by CETP inhibition has been suggested to be asso-
ciated with increases of both HDL-C concentration and
cholesterol efﬂux capacity per HDL particle.11,12,15 All
together, these results support thehypothesis thatHDLparticles
are still functional after treatment with strong CETP inhibitors.
The present study also showed that almost complete
washout of evacetrapib occurred within the 4- to 6-week
reversal period after 12 weeks of evacetrapib monotherapy
as well as in combination with atorvastatin. The effects on
lipids (HDL-C and LDL-C) and CETP mass and activity
were no longer apparent after 4 to 6 weeks of drug cessation,
consistent with evacetrapib blood levels that were near or
below the quantitation limit of the assay. These observations
are consistent with the terminal half-life of evacetrapib.16
In contrast, persistent plasma anacetrapib concentrations
and signiﬁcant lipid changes (LDL-C and HDL-C) were
observed 8 weeks after the last dose of anacetrapib (given
for 8 weeks at 100 or 300 mg/day dose).3 Approximately
20% of the plasma anacetrapib concentrations remained at
each anacetrapib dose as monotherapy or in coadministra-
tion with atorvastatin. Approximately 1/3 to 1/2 of the effect
on LDL-C and approximately 1/5 to 1/2 of the effect on
HDL-C with anacetrapib at week 8 were still observed
8 weeks after anacetrapib cessation. Moreover, Gotto et al2
have also recently shown that signiﬁcant concentrations of
anacetrapib are still measurable in plasma 12 weeks after
cessation of treatment in the 76-week DEFINE study,
strongly suggesting that evacetrapib and anacetrapib differ
in the way they are distributed and/or eliminated.
Preventive Cardiology/Evacetrapib in Japanese Patients With Dyslipidemia 2029The present study also demonstrated that 12-week therapy
with daily doses of evacetrapib up to 500mg as monotherapy,
or daily doses of evacetrapib 100 mg in combination with
atorvastatin 10 mg, was well tolerated, with a low number of
treatment-related adverse events in Japanese patients with
high LDL-C or low HDL-C levels. Administration of evac-
etrapib as monotherapy or in combination with atorvastatin
was not likely to be associated with any signiﬁcant change in
either SBP or DBP at any time point. The isolated ﬁnding of
increased SBP with evacetrapib 500 mg appears to be an
incidental occurrence, because neither a dose-dependent
effect of evacetrapib monotherapy on SBP nor an increase
in SBPwith evacetrapib in combination with atorvastatin was
observed. In addition, SBP also increased 2.6 1.8mmHg in
the atorvastatin monotherapy group, thus showing inherent
variability in BP measurements.
It is worth noting that evacetrapib did not have any adverse
effects on mineralocorticoid or electrolyte measures, thus
agreeing with data reported in the phase 2 study of evacetrapib
in the United States and Europe,6 in the phase 2 study of ana-
cetrapib,17 and in the phase 3 study of dalcetrapib.18The lack of
unfavorable changes in mineralocorticoid and electrolyte pa-
rameters for evacetrapib, anacetrapib, and dalcetrapib further
support the hypothesis that the safety ﬁndings demonstrated
with the previously terminated CETP inhibitor, torcetrapib,
were most likely off-target effects and not related to the CETP
mechanism.1 Preclinical data also support the lack of negative
effects of evacetrapib on the renin-angiotensin-aldosterone
system.4 No BP elevation was observed in rats, dogs, or cyn-
omolgus monkeys dosed with evacetrapib at high-exposure
multiples compared with torcetrapib. In addition, in a human
adrenal cortical carcinoma cell line (H295R cells), torcetrapib
dramatically induced aldosterone and cortisol biosynthesis,
whereas evacetrapib did not have any effect.4Acknowledgment: The authors wish to acknowledge the
investigators and patients who participated in this study and
Stephanie Brillhart, MSCI, of inVentiv Health Clinical for
providing writing assistance.Disclosures
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